Vaccinex, Inc.
NASDAQ:VCNX
1.31 (USD) • At close December 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Vaccinex, Inc. |
Symbool | VCNX |
Munteenheid | USD |
Prijs | 1.31 |
Beurswaarde | 3,506,398 |
Dividendpercentage | 0% |
52-weken bereik | 0.76 - 13.02 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Maurice Zauderer Ph.D. |
Website | https://www.vaccinex.com |
An error occurred while fetching data.
Over Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)